ArticleFrontiers in pharmacology2026
The impact of magnesium sulfate administration on outcomes in ICU patients with acute myocardial infarction: a retrospective cohort study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although magnesium acts as a natural calcium antagonist with theoretical cardioprotective effects, its clinical value in critically ill patients with acute myocardial infarction (AMI) remains controversial. This study aimed to evaluate the impact of intravenous magnesium sulfate on ICU mortality in this population, and to explore potential dose-response relationships and effect modifiers. Methods: This retrospective cohort study utilized the single-center Medical Information Mart for Intensive Care-IV version 3.1 (MIMIC-IV v3.1) database, which comprises patients admitted to Beth Israel Deaconess Medical Center, to examine the association between intravenous magnesium sulfate administration and mortality in critically ill patients with AMI. The primary endpoint was ICU mortality. Multivariable Cox regression, propensity score matching, and propensity score weighting were employed to control for confounders and estimate the independent effect of magnesium sulfate administration. Additional analyses included assessment of the restricted mean survival time (RMST) and quantitative evaluation of unmeasured confounding using the E-value. Results: This study included 5,650 critically ill patients with AMI. In the propensity score-matched analysis, intravenous magnesium sulfate administration was associated with a 45% reduction in ICU mortality risk (HR 0.55, 95% CI 0.42-0.71). RMST analysis confirmed an absolute survival benefit of 1.64 days at 14 days. A consistent reduction in mortality risk was observed across all secondary endpoints. A clear dose-response relationship was identified, with the greatest survival benefit at moderate cumulative doses (2.0-8.0 g) and treatment durations (1.08-3.21 days). The association remained robust to potential unmeasured confounding (E-value = 2.66). Subgroup analyses demonstrated consistent protective effects across all patient strata. Conclusion: Intravenous magnesium sulfate administration is associated with lower ICU mortality in critically ill patients with AMI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.